Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v8-FR
Language French French
Date Updated 2024-11-08 2024-11-04
Drug Identification Number 02529602 02529602
Brand name MYXREDLIN MYXREDLIN
Common or Proper name MYXREDLIN Human Insulin 100 units / 100 mL in 0.9% Sodium Chloride MYXREDLIN Human Insulin 100 units / 100 mL in 0.9% Sodium Chloride
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients INSULIN INSULIN
Strength(s) 1UNIT 1UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes CA2G3322 CA2G3322
ATC code A10AB A10AB
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2024-10-28 2024-10-28
Actual start date 2024-10-28 2024-10-28
Estimated end date 2024-11-15 2024-11-08
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments This is the only Ready to Use Insulin in the market. Many hospitals have converted to this format for safety. We will be stocking out many hospitals and are dependent on this release from Health Canada. This is the only Ready to Use Insulin in the market. Many hospitals have converted to this format for safety. We will be stocking out many hospitals and are dependent on this release from Health Canada.
Health Canada comments